Highly efficient, In-vivo Fas-mediated Apoptosis of B-cell Lymphoma by Hexameric CTLA4-FasL

Non-Hodgkin lymphomas (NHLs) account for 4% of all malignancies. 5-year survival rate increased to 50% with new treatment modalities, however there is need for new effective treatment for the more aggressive, relapsing forms. Recently, CTLA4-FasL, that can bind to B7 and Fas receptor (Fas), was show...

Full description

Saved in:
Bibliographic Details
Main Authors: Aronin, Alexandra, Amsili, Shira, Prigozhina, Tatyana B, Tzdaka, Kobi, Shen, Roy, Grinmann, Leonid, Szafer, Fanny, Edebrink, Per, Rauvola, Mari-Anne, Shani, Noam, Elhalel, Michal Dranitzki
Format: Artigo
Language:Inglês
Published: BioMed Central 2014
Subjects:
Research
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4189725/
https://ncbi.nlm.nih.gov/pubmed/25227919
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-014-0064-6
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items